ClinicalTrials.gg

Program

drospirenone

Also written as “15 mg E4/3 mg DRSP”, “Drospirenone” and “0.25mg DRSP / 0.5mg E2 (BAY86-4891)”.

Its studies are mostly in Hot Flashes · Bone Diseases, Metabolic · Contraception Behavior · Overweight · Hemorrhage, led by 4 companies.

Furthest: phase 4, since Sep 12, 200515 company-led studies, 1 open or runningNext primary completion: Dec 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayer60 open or runningphase 4since Sep 12, 2005Sep 12, 2005none ahead
Estetra60 open or runningphase 3since Jun 27, 2016Apr 15, 2016none ahead
Insud Pharma21 open or runningphase 4since Mar 22, 2022Mar 22, 2022Dec 2027phase 4 · NCT05303636
Laboratories Leon Farma10 open or runningphase 3since Oct 6, 2014Oct 6, 2014none ahead

Also a collaborator on its studies: chemo-research, novum, pra-health-sciences, chemo-france and quotient-sciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 12, 2005First study: phase 4 study in PostmenopauseNew to BayerBayer · NCT00185328 · 55 enrolled
  2. Jul 25, 2006Phase 3 study in Vasomotor SymptomsBayer · NCT00356447 · 249 enrolled · China
  3. Mar 9, 2007Phase 3 study in Hot FlashesBayer · NCT00446199 · 735 enrolled · United States
  4. Apr 17, 2007Phase 3 study in DysmenorrheaBayer · NCT00461305 · 420 enrolled · Japan
  5. Aug 29, 2007Phase 3 study in Hot FlashesBayer · NCT00522873 · 662 enrolled · United States, Argentina, Austria and more
  6. Apr 2, 2008Phase 2 study in Contraceptive, Oral, HormonalBayer · NCT00653614 · 635 enrolled · Germany
  7. Oct 6, 2014Laboratories Leon Farma's first study: phase 3 study in ContraceptionNew to Laboratories Leon FarmaLaboratories Leon Farma · NCT02269241 · 1,552 enrolled · United States
  8. Apr 15, 2016Estetra's first study: phase 1 study in ContraceptionNew to EstetraEstetra · NCT02852681 · 28 enrolled
  9. Jun 27, 20162 phase 3 studies in ContraceptionEstetra · NCT02817841, NCT02817828
  10. Oct 25, 2016Phase 2 study in ContraceptionEstetra · NCT02957630 · 101 enrolled · Netherlands
  11. Mar 21, 2017Phase 2 study in Prevention of PregnancyEstetra · NCT03091595 · 82 enrolled · Netherlands
  12. Apr 19, 2018Phase 1 study in ContraceptionEstetra · NCT03512860 · 24 enrolled · United Kingdom
  13. Mar 22, 2022Insud Pharma's first study: phase 4 study in Bone Diseases, MetabolicNew to Insud PharmaInsud Pharma · NCT05303636 · 1,536 enrolled · United States, Czechia, Poland
  14. Jun 30, 2022Phase 3 study in Contraception BehaviorInsud Pharma · NCT05461573 · 1,542 enrolled · United States, Canada

Ahead

  1. Dec 2027Primary completion: phase 4 study in Bone Diseases, MetabolicInsud Pharma · NCT05303636

TargetBeta

NR3C2 →PGR →read by rule
“Mineralocorticoid receptor antagonist; Progesterone receptor agonist”ChEMBL 37, by rule

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT05461573Contraception Behavior · United States, Canada3CompletedInsud PharmaAug 5, 20241,542
NCT05303636Bone Diseases, Metabolic · United States, Czechia, Poland4Active, not recruitingInsud PharmaDec 20271,536
NCT03512860Contraception · United Kingdom1CompletedEstetraOct 8, 201824
NCT03091595Prevention of Pregnancy · Netherlands2CompletedEstetraJun 8, 201882
NCT02957630Contraception · Netherlands2CompletedEstetraOct 9, 2017101
NCT02817841Contraception · United States, Canada3CompletedEstetraOct 16, 20182,148
NCT02817828Contraception · Belgium3CompletedEstetraApr 26, 20181,577
NCT02852681Contraception1CompletedEstetraOct 201528
NCT02269241Contraception · United States3CompletedLaboratories Leon FarmaOct 4, 20171,552
NCT00653614Contraceptive, Oral, Hormonal · Germany2CompletedBayerJun 2009635
NCT00522873Hot Flashes · United States, Argentina, Austria and more3CompletedBayerAug 2009662
NCT00461305Dysmenorrhea · Japan3CompletedBayerJan 2009420
NCT00446199Hot Flashes · United States3CompletedBayerOct 2008735
NCT00356447Vasomotor Symptoms · China3CompletedBayerOct 2007249
NCT00185328Postmenopause4CompletedBayer55

How it is read

Names in the registry

  • “15 mg E4/3 mg DRSP”, 5 entries
  • “Drospirenone”, 2 entries
  • “0.25mg DRSP / 0.5mg E2 (BAY86-4891)”, 2 entries
  • “Estradiol/DRSP (Angeliq, BAY86-4891)”, 2 entries
  • “drospirenone”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.